Research ExplorerPublicationsSequential combination therapy leads to biochemical and hist...

Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.

Standard

Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. / Lütgehetmann, Marc; Volz, Tassilo; Quaas, Alexander; Zankel, Myrga; Fischer, Conrad; Dandri-Petersen, Maura; Petersen, Jörg.

In: ANTIVIR THER, Vol. 13, No. 1, 1, 2008, p. 57-66.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lütgehetmann, M, Volz, T, Quaas, A, Zankel, M, Fischer, C, Dandri-Petersen, M & Petersen, J 2008, 'Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.', ANTIVIR THER, vol. 13, no. 1, 1, pp. 57-66. <http://www.ncbi.nlm.nih.gov/pubmed/18389899?dopt=Citation>

APA

Lütgehetmann, M., Volz, T., Quaas, A., Zankel, M., Fischer, C., Dandri-Petersen, M., & Petersen, J. (2008). Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. ANTIVIR THER, 13(1), 57-66. [1]. http://www.ncbi.nlm.nih.gov/pubmed/18389899?dopt=Citation

Vancouver

Lütgehetmann M, Volz T, Quaas A, Zankel M, Fischer C, Dandri-Petersen M et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. ANTIVIR THER. 2008;13(1):57-66. 1.

Bibtex

@article{4c418bddae8f4c12bcc89546531caa27,
title = "Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.",
abstract = "BACKGROUND: We previously reported that 48 weeks of combination therapy with pegylated interferon-alpha2b (PEG-IFN-alpha2b) and adefovir dipivoxil (ADV) in patients with chronic hepatitis B led to marked decreases of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) (-2.4 log10 copies/ml). Combination therapy was followed by 96 weeks of ADV monotherapy. METHODS: Here, we report on the final outcome after 144 weeks of sequential antiviral treatment. Twenty-four patients were analysed, triplet liver biopsies (taken at baseline, week 48 and week 144) were available from 16 patients. RESULTS: At week 144, 12/15 patients positive for hepatitis B virus e antigen (HBeAg) had lost HBeAg, alanine transaminase (ALT) levels were normal in 23 patients (96%), median serum HBV DNA had decreased by -4.9 log10 copies/ml and was undetectable (",
author = "Marc L{\"u}tgehetmann and Tassilo Volz and Alexander Quaas and Myrga Zankel and Conrad Fischer and Maura Dandri-Petersen and J{\"o}rg Petersen",
year = "2008",
language = "Deutsch",
volume = "13",
pages = "57--66",
journal = "ANTIVIR THER",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.

AU - Lütgehetmann, Marc

AU - Volz, Tassilo

AU - Quaas, Alexander

AU - Zankel, Myrga

AU - Fischer, Conrad

AU - Dandri-Petersen, Maura

AU - Petersen, Jörg

PY - 2008

Y1 - 2008

N2 - BACKGROUND: We previously reported that 48 weeks of combination therapy with pegylated interferon-alpha2b (PEG-IFN-alpha2b) and adefovir dipivoxil (ADV) in patients with chronic hepatitis B led to marked decreases of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) (-2.4 log10 copies/ml). Combination therapy was followed by 96 weeks of ADV monotherapy. METHODS: Here, we report on the final outcome after 144 weeks of sequential antiviral treatment. Twenty-four patients were analysed, triplet liver biopsies (taken at baseline, week 48 and week 144) were available from 16 patients. RESULTS: At week 144, 12/15 patients positive for hepatitis B virus e antigen (HBeAg) had lost HBeAg, alanine transaminase (ALT) levels were normal in 23 patients (96%), median serum HBV DNA had decreased by -4.9 log10 copies/ml and was undetectable (

AB - BACKGROUND: We previously reported that 48 weeks of combination therapy with pegylated interferon-alpha2b (PEG-IFN-alpha2b) and adefovir dipivoxil (ADV) in patients with chronic hepatitis B led to marked decreases of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) (-2.4 log10 copies/ml). Combination therapy was followed by 96 weeks of ADV monotherapy. METHODS: Here, we report on the final outcome after 144 weeks of sequential antiviral treatment. Twenty-four patients were analysed, triplet liver biopsies (taken at baseline, week 48 and week 144) were available from 16 patients. RESULTS: At week 144, 12/15 patients positive for hepatitis B virus e antigen (HBeAg) had lost HBeAg, alanine transaminase (ALT) levels were normal in 23 patients (96%), median serum HBV DNA had decreased by -4.9 log10 copies/ml and was undetectable (

M3 - SCORING: Zeitschriftenaufsatz

VL - 13

SP - 57

EP - 66

JO - ANTIVIR THER

JF - ANTIVIR THER

SN - 1359-6535

IS - 1

M1 - 1

ER -